Tonucci Paolo 4
4 · Marex Group plc · Filed Apr 15, 2026
Research Summary
AI-generated summary of this filing
Marex (MRX) Chief Strategist & CEO Paolo Tonucci Sells Shares
What Happened
Paolo Tonucci, Chief Strategist and CEO, Capital Markets at Marex Group plc (MRX), sold a total of 16,666 ordinary shares in open‑market/private sales on April 13, 2026 for aggregate proceeds of approximately $856,049. The trades were reported as three disposals: 6,760 shares at a weighted‑average price of $50.60 ($342,064), 5,829 shares at $51.56 ($300,522), and 4,077 shares at $52.36 ($213,463). These sales were made pursuant to a Rule 10b5‑1 trading plan entered October 22, 2025.
Key Details
- Transaction date: April 13, 2026 (reported on Form 4 filed April 15, 2026); filing appears timely.
- Trades (all sales):
- 6,760 shares @ weighted avg $50.60 — proceeds $342,064 (prices in range $50.07–$51.065).
- 5,829 shares @ weighted avg $51.56 — proceeds $300,522 (prices in range $51.08–$52.065).
- 4,077 shares @ weighted avg $52.36 — proceeds $213,463 (prices in range $52.09–$52.65).
- Total shares sold: 16,666; total proceeds: ~$856,049.
- Footnotes: sale executed under a 10b5‑1 plan (F1); each reported weighted price covers a range of execution prices and the reporting person will provide breakdowns on request (F2–F4). The filing also notes 286,871 shares underlying deferred bonus awards included in reported holdings (F5).
- Shares owned after the transactions are not specified in the excerpt provided.
Context
These are outright sales under a pre‑arranged 10b5‑1 plan, which is commonly used by insiders to sell shares according to a schedule and reduces concerns about trading on inside information. Sales do not necessarily signal a change in view of the company; retail investors should consider this as a routine insider disposition unless accompanied by other material company news.
Insider Transaction Report
- Sale
Ordinary Shares
[F1][F2]2026-04-13$50.60/sh−6,760$342,064→ 1,373,263 total - Sale
Ordinary Shares
[F1][F3]2026-04-13$51.56/sh−5,829$300,522→ 1,367,434 total - Sale
Ordinary Shares
[F1][F4][F5]2026-04-13$52.36/sh−4,077$213,463→ 1,363,357 total
Footnotes (5)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $50.07 to $51.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $51.08 to $52.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $52.09 to $52.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The number of ordinary shares reported herein includes 286,871 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.